Manoel Jairo bezerra e os livros didáticos / Manoel Jairo bezerra and the teaching books

Essa comunicação tem por objetivo apresentar os resultados parciais da segunda etapa da pesquisa intitulada Manoel Jairo Bezerra, a Matemática e a Radiodifusão Educativa no Brasil. Nessa fase o objetivo é a localização e a catalogação dos livros didáticos escritos pelo Professor Manoel Jairo Bezerra, falecido no ano de 2010. Trata-se de um estudo biográfico cuja análise de livros didáticos foi influenciada por Alain Chopin e seu estudo sobre a História dos Livros e das Edições Didáticas. Também apresentamos um estudo bibliográfico dirigido e que diz respeito aos trabalhos acadêmicos nos quais Manoel Jairo Bezerra foi citado. Concluímos que Manoel Jairo Bezerra publicou boa parte dos seus livros através de instituições governamentais federais e que o auge de sua produção bibliográfica ocorreu na década de 1960.

AVALIAÇÃO DO CONHECIMENTO E DO ESTADO NUTRICIONAL DE PACIENTES COM CÂNCER EM UM HOSPITAL PÚBLICO DO INTERIOR PAULISTA

Weight loss in cancer occurs both through disease and treatment. The objective was to evaluate the nutritional knowledge of cancer patients and their nutritional status. This was an observational, descriptive study of 50 cancer patients, over 19 years old, admitted to a public hospital in the interior of São Paulo. Nutritional knowledge, anthropometric profile and weight loss were evaluated. For data analysis, the frequencies, mean and standard deviation of continuous variables were calculated and presented in the form of tables, charts and graphs of sectors. 44% of the patients had severe weight loss before the diagnosis of the disease until the moment of the research and a greater weight loss was evident in those patients who presented medium and low nutritional knowledge. It is necessary to create educational food and nutrition actions aimed at improving knowledge and eating behavior, in order to answer questions and improve their nutritional status.A perda de peso no câncer ocorre tanto pela doença como pelo tratamento. Objetivou-se avaliar o conhecimento nutricional dos pacientes com câncer e seu estado nutricional.  Tratou-se de um estudo observacional, descritivo em 50 pacientes com câncer, acima de 19 anos, internados em um hospital público do interior paulista. Foram avaliados o conhecimento nutricional, o perfil antropométrico e a perda de peso. Para a análise dos dados foram calculados as frequências, média e desvio-padrão das variáveis contínuo e apresentado em forma de tabelas, quadros e gráficos de setores. 44% dos pacientes apresentaram perda de peso grave antes do diagnóstico da doença até o momento da pesquisa e uma maior perda de peso foi evidente naqueles pacientes que apresentaram médio e baixo conhecimento nutricional. É necessário criar ações educativas alimentares e nutricionais voltadas para a melhoria do conhecimento e comportamento alimentar, a fim de esclarecer dúvidas e melhorar seu estado nutricional

Avaliação das condições de superfície de pavimento rígido na Rodovia BR-232 e correlação com o índice de acidentes rodoviários / Evaluation of rigid floor surface conditions in the BR-232 Road and correlation with the road accident index

Parte da malha rodoviária do Brasil é composta por pavimento rígido, e pode apresentar manifestações patológicas decorrentes de falhas de projetos e execução, falta de manutenções, sobrecarga dos veículos, fatores climáticos degradantes e ou geometria irregular comprometem a vida útil do pavimento. Desta forma este trabalho objetivou analisar qualitativamente e quantitativamente o pavimento de concreto rígido, em um trecho da BR 232/PE nos Km 71,5 ao Km 115, a partir do levantamento e caracterização das manifestações patológicas confrontando-as com o número de acidentes ocorridos na área entre os anos de 2012 a 2016 segundo o Sistema Integrado de Operações Rodoviárias – SIOR. Esta análise classificou o trecho conforme nível de conservação, incidência de manifestações patológicas e grau de desconforto para posterior categorização conforme o índice de Condição do Pavimento - ICP. Os resultados demonstraram que apesar de trechos apresentarem condições de conservação péssimas, numa análise geral o estado da via se encontra em condições razoáveis de trafegabilidade e segurança dos usuários, não apresentando uma relação significativa entre o número de acidentes e as manifestações patológicas do pavimento

Cuidando de quem nos cuida: Uma proposta de ação acerca da qualidade de vida do trabalhador / Taking care of those who care for us: A proposed action on the worker's quality of life

Objetivo: Descrever uma ação voltada para a saúde do trabalhador, com intervenções educativas e Práticas Integrativas e Complementares em Saúde. Métodos: Trata-se de um relato de experiência de cunho descritivo, sobre uma ação realizada em comemoração ao dia do servidor público, em quatro etapas na Universidade do Estado do Pará, localizada na cidade de Tucuruí/PA, em outubro de 2019. Relato de experiência: Participaram do evento 42 funcionários do centro universitário do sistema de educação público do município em estudo, sendo no total 24 do sexo feminino e 18 do masculino, entre a faixa etária de 18 a 60 anos de idade. Dessa forma, para a melhor interação do público alvo, realizou-se um planejamento dos temas sobre a saúde mental e nutrição dos trabalhadores e a constelação familiar. Conclusão: Ações voltadas para   o equilíbrio biopsicossocial dos trabalhadores, são fundamentais para o seu bem estar, bem como sua qualidade de vida. Ressalta-se, portanto, a necessidade promoção   intervenções para a saúde deste público em questão

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: The authors would like to thank all patients and their families and all the EMMOS investigators for their valuable contributions to the study. The authors would like to acknowledge Robert Olie for his significant contribution to the EMMOS study. Writing support during the development of our report was provided by Laura Mulcahy and Catherine Crookes of FireKite, an Ashfield company, a part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc, and Janssen Global Services, LLC. The EMMOS study was supported by research funding from Janssen Pharmaceutical NV and Millennium Pharmaceuticals, Inc. Funding Information: M.M. has received personal fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Sanofi, Novartis, and Takeda and grants from Janssen and Sanofi during the conduct of the study. E.T. has received grants from Janssen and personal fees from Janssen and Takeda during the conduct of the study, and grants from Amgen, Celgene/Genesis, personal fees from Amgen, Celgene/Genesis, Bristol-Myers Squibb, Novartis, and Glaxo-Smith Kline outside the submitted work. M.V.M. has received personal fees from Janssen, Celgene, Amgen, and Takeda outside the submitted work. M.C. reports honoraria from Janssen, outside the submitted work. M. B. reports grants from Janssen Cilag during the conduct of the study. M.D. has received honoraria for participation on advisory boards for Janssen, Celgene, Takeda, Amgen, and Novartis. H.S. has received honoraria from Janssen-Cilag, Celgene, Amgen, Bristol-Myers Squibb, Novartis, and Takeda outside the submitted work. V.P. reports personal fees from Janssen during the conduct of the study and grants, personal fees, and nonfinancial support from Amgen, grants and personal fees from Sanofi, and personal fees from Takeda outside the submitted work. W.W. has received personal fees and grants from Amgen, Celgene, Novartis, Roche, Takeda, Gilead, and Janssen and nonfinancial support from Roche outside the submitted work. J.S. reports grants and nonfinancial support from Janssen Pharmaceutical during the conduct of the study. V.L. reports funding from Janssen Global Services LLC during the conduct of the study and study support from Janssen-Cilag and Pharmion outside the submitted work. A.P. reports employment and shareholding of Janssen (Johnson & Johnson) during the conduct of the study. C.C. reports employment at Janssen-Cilag during the conduct of the study. C.F. reports employment at Janssen Research and Development during the conduct of the study. F.T.B. reports employment at Janssen-Cilag during the conduct of the study. The remaining authors have stated that they have no conflicts of interest. Publisher Copyright: © 2018 The AuthorsMultiple myeloma (MM) remains an incurable disease, with little information available on its management in real-world clinical practice. The results of the present prospective, noninterventional observational study revealed great diversity in the treatment regimens used to treat MM. Our results also provide data to inform health economic, pharmacoepidemiologic, and outcomes research, providing a framework for the design of protocols to improve the outcomes of patients with MM. Background: The present prospective, multinational, noninterventional study aimed to document and describe real-world treatment regimens and disease progression in multiple myeloma (MM) patients. Patients and Methods: Adult patients initiating any new MM therapy from October 2010 to October 2012 were eligible. A multistage patient/site recruitment model was applied to minimize the selection bias; enrollment was stratified by country, region, and practice type. The patient medical and disease features, treatment history, and remission status were recorded at baseline, and prospective data on treatment, efficacy, and safety were collected electronically every 3 months. Results: A total of 2358 patients were enrolled. Of these patients, 775 and 1583 did and did not undergo stem cell transplantation (SCT) at any time during treatment, respectively. Of the patients in the SCT and non-SCT groups, 49%, 21%, 14%, and 15% and 57%, 20%, 12% and 10% were enrolled at treatment line 1, 2, 3, and ≥ 4, respectively. In the SCT and non-SCT groups, 45% and 54% of the patients had received bortezomib-based therapy without thalidomide/lenalidomide, 12% and 18% had received thalidomide/lenalidomide-based therapy without bortezomib, and 30% and 4% had received bortezomib plus thalidomide/lenalidomide-based therapy as frontline treatment, respectively. The corresponding proportions of SCT and non-SCT patients in lines 2, 3, and ≥ 4 were 45% and 37%, 30% and 37%, and 12% and 3%, 33% and 27%, 35% and 32%, and 8% and 2%, and 27% and 27%, 27% and 23%, and 6% and 4%, respectively. In the SCT and non-SCT patients, the overall response rate was 86% to 97% and 64% to 85% in line 1, 74% to 78% and 59% to 68% in line 2, 55% to 83% and 48% to 60% in line 3, and 49% to 65% and 36% and 45% in line 4, respectively, for regimens that included bortezomib and/or thalidomide/lenalidomide. Conclusion: The results of our prospective study have revealed great diversity in the treatment regimens used to manage MM in real-life practice. This diversity was linked to factors such as novel agent accessibility and evolving treatment recommendations. Our results provide insight into associated clinical benefits.publishersversionPeer reviewe

Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

A cross-ancestry genome-wide association meta-analysis of amyotrophic lateral sclerosis (ALS) including 29,612 patients with ALS and 122,656 controls identifies 15 risk loci with distinct genetic architectures and neuron-specific biology. Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with a lifetime risk of one in 350 people and an unmet need for disease-modifying therapies. We conducted a cross-ancestry genome-wide association study (GWAS) including 29,612 patients with ALS and 122,656 controls, which identified 15 risk loci. When combined with 8,953 individuals with whole-genome sequencing (6,538 patients, 2,415 controls) and a large cortex-derived expression quantitative trait locus (eQTL) dataset (MetaBrain), analyses revealed locus-specific genetic architectures in which we prioritized genes either through rare variants, short tandem repeats or regulatory effects. ALS-associated risk loci were shared with multiple traits within the neurodegenerative spectrum but with distinct enrichment patterns across brain regions and cell types. Of the environmental and lifestyle risk factors obtained from the literature, Mendelian randomization analyses indicated a causal role for high cholesterol levels. The combination of all ALS-associated signals reveals a role for perturbations in vesicle-mediated transport and autophagy and provides evidence for cell-autonomous disease initiation in glutamatergic neurons

Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy

Because hyper-excitability has been shown to be a shared pathophysiological mechanism, we used the latest and largest genome-wide studies in amyotrophic lateral sclerosis (n = 36,052) and epilepsy (n = 38,349) to determine genetic overlap between these conditions. First, we showed no significant genetic correlation, also when binned on minor allele frequency. Second, we confirmed the absence of polygenic overlap using genomic risk score analysis. Finally, we did not identify pleiotropic variants in meta-analyses of the 2 diseases. Our findings indicate that amyotrophic lateral sclerosis and epilepsy do not share common genetic risk, showing that hyper-excitability in both disorders has distinct origins

Sex difference and intra-operative tidal volume: Insights from the LAS VEGAS study

BACKGROUND: One key element of lung-protective ventilation is the use of a low tidal volume (VT). A sex difference in use of low tidal volume ventilation (LTVV) has been described in critically ill ICU patients.OBJECTIVES: The aim of this study was to determine whether a sex difference in use of LTVV also exists in operating room patients, and if present what factors drive this difference.DESIGN, PATIENTS AND SETTING: This is a posthoc analysis of LAS VEGAS, a 1-week worldwide observational study in adults requiring intra-operative ventilation during general anaesthesia for surgery in 146 hospitals in 29 countries.MAIN OUTCOME MEASURES: Women and men were compared with respect to use of LTVV, defined as VT of 8 ml kg-1 or less predicted bodyweight (PBW). A VT was deemed 'default' if the set VT was a round number. A mediation analysis assessed which factors may explain the sex difference in use of LTVV during intra-operative ventilation.RESULTS: This analysis includes 9864 patients, of whom 5425 (55%) were women. A default VT was often set, both in women and men; mode VT was 500 ml. Median [IQR] VT was higher in women than in men (8.6 [7.7 to 9.6] vs. 7.6 [6.8 to 8.4] ml kg-1 PBW, P < 0.001). Compared with men, women were twice as likely not to receive LTVV [68.8 vs. 36.0%; relative risk ratio 2.1 (95% CI 1.9 to 2.1), P < 0.001]. In the mediation analysis, patients' height and actual body weight (ABW) explained 81 and 18% of the sex difference in use of LTVV, respectively; it was not explained by the use of a default VT.CONCLUSION: In this worldwide cohort of patients receiving intra-operative ventilation during general anaesthesia for surgery, women received a higher VT than men during intra-operative ventilation. The risk for a female not to receive LTVV during surgery was double that of males. Height and ABW were the two mediators of the sex difference in use of LTVV.TRIAL REGISTRATION: The study was registered at Clinicaltrials.gov, NCT01601223

Optimasi Portofolio Resiko Menggunakan Model Markowitz MVO Dikaitkan dengan Keterbatasan Manusia dalam Memprediksi Masa Depan dalam Perspektif Al-Qur`an

Risk portfolio on modern finance has become increasingly technical, requiring the use of sophisticated mathematical tools in both research and practice. Since companies cannot insure themselves completely against risk, as human incompetence in predicting the future precisely that written in Al-Quran surah Luqman verse 34, they have to manage it to yield an optimal portfolio. The objective here is to minimize the variance among all portfolios, or alternatively, to maximize expected return among all portfolios that has at least a certain expected return. Furthermore, this study focuses on optimizing risk portfolio so called Markowitz MVO (Mean-Variance Optimization). Some theoretical frameworks for analysis are arithmetic mean, geometric mean, variance, covariance, linear programming, and quadratic programming. Moreover, finding a minimum variance portfolio produces a convex quadratic programming, that is minimizing the objective function ðð¥with constraintsð ð 𥠥 ðandð´ð¥ = ð. The outcome of this research is the solution of optimal risk portofolio in some investments that could be finished smoothly using MATLAB R2007b software together with its graphic analysis

Penilaian Kinerja Keuangan Koperasi di Kabupaten Pelalawan

This paper describe development and financial performance of cooperative in District Pelalawan among 2007 - 2008. Studies on primary and secondary cooperative in 12 sub-districts. Method in this stady use performance measuring of productivity, efficiency, growth, liquidity, and solvability of cooperative. Productivity of cooperative in Pelalawan was highly but efficiency still low. Profit and income were highly, even liquidity of cooperative very high, and solvability was good